Microbix Biosystems Inc. saw its stock price drop by 3.23% in the latest trading session, reflecting ongoing investor concerns.
Microbix Biosystems Inc. (MBX.TO) experienced a decline of 3.23% in its stock price during the last trading session, closing at CA$0.30. This downward movement raises questions about the company's performance and future prospects amidst a challenging market environment.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$41.94M
52W high
$0.34
52W low
$0.21
1W change
+3.33%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 29.0% over the next 12 months.
Consensus
No RatingAvg. Target
C$0.40
+29.0% Upside
Current Price
C$0.31
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
42.4%
Annualized
90-Day Vol
54.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.37
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.33 | C$0.28 โ C$0.38 |
| 60 trading days | C$0.35 | C$0.28 โ C$0.43 |
| 90 trading days | C$0.37 | C$0.29 โ C$0.48 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Microbix's financial health and market strategies, especially given the recent net loss reported in their Q1 results.
Microbix Biosystems Inc. Market Cap: CA$42.6 Million
With a market cap of CA$42.6 million and a profit margin of -38.62%, Microbix faces significant financial challenges that could impact investor confidence.
Bull case
Microbix reported a 13% increase in revenues for Q1 2026, which suggests that there may be potential growth in its core business, despite the current stock performance.
Bear case
The company's ongoing net losses and lack of a dividend yield might deter investors, especially in a market that rewards profitability and returns.
Recent Performance Overview
In the latest trading session, Microbix Biosystems Inc. saw its stock price decrease by 3.23%, closing at CA$0.30. This decline comes amid investor scrutiny following their recent Q1 2026 financial results, which showed a controlled net loss despite a revenue increase.
Market Sentiment and Future Outlook
The negative market reaction may stem from ongoing concerns about Microbix's profitability, highlighted by its significant negative profit margin of -38.62%. Investors are urged to consider the company's strategic plans and how they may address these financial challenges moving forward. For more insights, check out the latest updates on Microbix's Q1 results and their expansion plans.
Advertisement
